Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission

PloS One
Cornelis R van der TorrenLothar Hambach

Abstract

Persistent complete donor chimerism is an important clinical indicator for remissions of hematological malignancies after HLA-matched allogeneic stem cell transplantation (SCT). However, the mechanisms mediating the persistence of complete donor chimerism are poorly understood. The frequent coincidence of complete donor chimerism with graft-versus-leukemia effects and graft-versus-host disease suggests that immune responses against minor histocompatibility antigens (mHags) are playing an important role in suppressing the host hematopoiesis after allogeneic SCT. Here, we investigated a possible relationship between donor immune responses against the hematopoiesis-restricted mHag HA-1 and the long-term kinetics of host hematopoietic chimerism in a cohort of 10 patients after allogeneic HLA-matched, HA-1 mismatched SCT. Functional HA-1 specific CTLs (HA-1 CTLs) were detectable in 6/10 patients lysing host-type hematopoietic cells in vitro. Presence of HA-1 CTLs in the peripheral blood coincided with low host hematopoiesis levels quantified by highly sensitive mHag specific PCR. Additionally, co-incubation of host type CD34+ cells with HA-1 CTLs isolated after allogeneic SCT prevented progenitor and cobblestone area forming cell gr...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·D BonnetS R Riddell
Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·W A Erik MarijtJ H Frederik Falkenburg
Sep 23, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Martina WilkeEls Goulmy
Mar 16, 2005·Current Opinion in Immunology·Lothar Hambach, Els Goulmy
Jan 4, 2008·Cancer Research·William MatsuiRichard J Jones
Apr 4, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eric SpieringsEls Goulmy
Feb 9, 2010·Haematologica·Jose A Martinez-ClimentFelipe Prosper
Sep 21, 2010·Experimental Hematology·Bettina WiedemannUlrike Bacher
Oct 2, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Willemijn HoboHarry Dolstra
Jun 13, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric SpieringsEls Goulmy
Oct 24, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jae-Ho YoonChong-Won Park
Mar 22, 2014·PloS One·Miranda P DierselhuisEls Goulmy

❮ Previous
Next ❯

Citations

Jan 16, 2016·Proteomics. Clinical Applications·Charles T SpencerSebastian Joyce
May 10, 2017·PloS One·Kriti VermaLothar Hambach
May 4, 2018·Bone Marrow Transplantation·Lea SellmannLothar Hambach

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry
FCS
FACS
flowcytometry

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.